What we're reading, February 11, 2016: Plaintiffs lose their case against cigarette manufacturer; the politics behind providing care for those infected with Zika; and of course, prescription drug prices.
Longtime smokers of Marlboro cigarettes have lost their liability fight against the cigarette manufacturer Philip Morris USA. According to a report in the Chicago Tribune, a jury unanimously rejected a claim filed 10 years back that Marlboros are defective and dangerous. If they had won, the plaintiffs would have been eligible to receive screening chest scans estimated to cost $500.
Meanwhile, as the Zika virus continues its rampage in Latin America, the CDC believes Puerto Rico might be hit hard by the outbreak along with some other US territories. According to Reuters, CDC director Tom Frieden, MD, MPH, shared the information with the House Foreign Affairs subcommittee. Republican lawmakers who led the hearing, meanwhile, played abortion politics saying they hoped that infected women will not have abortions to avoid giving birth to children with developmental problems.
At another hearing on the Hill, HHS secretary Silvia Mathews Burwell was up defending the president’s budget—she told lawmakers that the administrations is delving into every option that can help control prescription drug prices. Burwell responded to Senator Jim McDermott’s (D-Washington) statement of support for Medicare to be able to negotiate prescription drug prices, saying that prescription prices are an increasing part of the Medicare budget and Veterans Administration has successfully negotiated lower prices.
Telephone Follow-Up on Medicare Patient Surveys Remains Critical
January 16th 2025Including a telephone component in Medicare Consumer Assessment of Healthcare Providers and Systems survey administration continues to be valuable because telephone responses comprise a substantial portion of responses for several underserved groups.
Read More
Quantifying the Altruism Value for a Rare Pediatric Disease: Duchenne Muscular Dystrophy
January 14th 2025Altruism values for treatments of rare, severe pediatric diseases have not been estimated. This study found the altruism value for a hypothetical new Duchenne muscular dystrophy treatment to be $80 per year.
Read More
Health Equity & Access Weekly Roundup: January 11, 2025
January 11th 2025ACA enrollment rate hits a milestone, though IRA subsidies may not extend beyond 2025; network adequacy standards fail to translate into efficient access to mental health care for Medicaid enrollees; research examines racial disparities in postpartum hypertension and vaccine uptake.
Read More